Saturday, July 11, 2026

Drug profile · INN

dihydroergotamine mesylate

dihydroergotamine mesylate (DIHYDROERGOTAMINE MESYLATE) is a serotonin 1d (5-ht1d) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dihydroergotamine mesylate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.89

Quick answer

dihydroergotamine mesylate (DIHYDROERGOTAMINE MESYLATE) is a serotonin 1d (5-ht1d) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN dihydroergotamine mesylate
Brand DIHYDROERGOTAMINE MESYLATE
Mechanism Serotonin 1d (5-HT1d) receptor agonist
Target 5-hydroxytryptamine receptor 1D
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Serotonin 1d (5-HT1d) receptor agonist

Primary target: 5-hydroxytryptamine receptor 1D

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. fenfluramine hydrochloride Serotonin 2c (5-HT2c) receptor agonist

Frequently asked questions

What is dihydroergotamine mesylate?

dihydroergotamine mesylate (DIHYDROERGOTAMINE MESYLATE) is a serotonin 1d (5-ht1d) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for dihydroergotamine mesylate?

DIHYDROERGOTAMINE MESYLATE is a marketed brand name for dihydroergotamine mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dihydroergotamine mesylate?

dihydroergotamine mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.